Crinetics Pharmaceuticals
6055 Lusk Blvd, San Diego, CA, 92121, United States
Overview
Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
- Therapeutics
Investment portfolio
- Radionetics Oncology
Participated · Series A · Jan 2024
Radionetics Oncology is a clinical-stage radiopharmaceutical company focused on discovering and developing novel small molecule radiotherapeutics that target GPCRs for a wide range of oncology indications. The company is advancing a pipeline of potent small molecule radioligands aimed at cancers including adrenocortical carcinoma, breast cancer, and lung cancer. Radionetics plans to use proceeds from its recent financing to advance this pipeline and further develop its GPCR-targeted radiopharmaceutical candidates. The company spun out of Crinetics Pharmaceuticals and is supported by investors including Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments. Radionetics recently completed a $52.5 million Series A, bringing total capital raised to date to $82.5 million. The company is based in San Diego and positions itself to be a leader in first-in-class radiopharmaceutical development.